• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心力衰竭中房颤的基因治疗

Gene Therapy for Atrial Fibrillation in Heart Failure.

作者信息

Arora R

机构信息

Department of Experimental Cardiac Electrophysiology, Northwestern University, Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, USA.

出版信息

Clin Pharmacol Ther. 2017 Aug;102(2):200-202. doi: 10.1002/cpt.717. Epub 2017 May 26.

DOI:10.1002/cpt.717
PMID:28548218
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6237284/
Abstract

Atrial fibrillation (AF) is the most common arrhythmia and a major cause of morbidity and mortality in an aging population. Unfortunately, current treatments for AF are suboptimal, in large part because the molecular mechanisms underlying AF are not well understood. Recent advances in our understanding of the AF disease state have led to the preclinical development of gene-based therapies that are targeted to key molecular mechanisms involved in the genesis and maintenance of AF.

摘要

心房颤动（AF）是最常见的心律失常，也是老年人群发病和死亡的主要原因。不幸的是，目前针对AF的治疗并不理想，很大程度上是因为AF的分子机制尚未完全明确。我们对AF疾病状态认识的最新进展促使了基于基因的疗法进入临床前开发阶段，这些疗法针对的是参与AF发生和维持的关键分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f5/6237284/f6c3a1d20794/nihms887544f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f5/6237284/f6c3a1d20794/nihms887544f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f5/6237284/f6c3a1d20794/nihms887544f1.jpg

相似文献

1
Gene Therapy for Atrial Fibrillation in Heart Failure.心力衰竭中房颤的基因治疗
Clin Pharmacol Ther. 2017 Aug;102(2):200-202. doi: 10.1002/cpt.717. Epub 2017 May 26.
2
Recent advances in gene therapy for atrial fibrillation.房颤的基因治疗新进展。
J Cardiovasc Electrophysiol. 2021 Oct;32(10):2854-2864. doi: 10.1111/jce.15116. Epub 2021 Jul 6.
3
Genome Editing and Atrial Fibrillation.基因组编辑与心房颤动。
Adv Exp Med Biol. 2023;1396:129-137. doi: 10.1007/978-981-19-5642-3_9.
4
Therapeutic Prospects of Gene Therapy for Atrial Fibrillation.心房颤动基因治疗的治疗前景
Heart Lung Circ. 2016 Aug;25(8):808-13. doi: 10.1016/j.hlc.2016.04.011. Epub 2016 May 12.
5
Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and fibrillation in the setting of heart failure.同步右房室起搏：一种用于研究心力衰竭情况下心房重塑和房颤的新型模型。
J Card Fail. 2008 Apr;14(3):254-62. doi: 10.1016/j.cardfail.2007.10.021.
6
Genetics of atrial fibrillation: an update.心房颤动的遗传学：最新进展
Curr Opin Cardiol. 2018 May;33(3):304-310. doi: 10.1097/HCO.0000000000000505.
7
MicroRNAs and atrial fibrillation: mechanisms and translational potential.微小 RNA 与心房颤动：机制与转化潜能。
Nat Rev Cardiol. 2015 Feb;12(2):80-90. doi: 10.1038/nrcardio.2014.178. Epub 2014 Nov 25.
8
Computational modeling: What does it tell us about atrial fibrillation therapy?计算模型：它能告诉我们关于房颤治疗的什么信息？
Int J Cardiol. 2019 Jul 15;287:155-161. doi: 10.1016/j.ijcard.2019.01.077. Epub 2019 Jan 25.
9
Biological Therapies for Atrial Fibrillation: Ready for Prime Time?心房颤动的生物疗法：准备好进入黄金时代了吗？
J Cardiovasc Pharmacol. 2016 Jan;67(1):19-25. doi: 10.1097/FJC.0000000000000293.
10
Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression.心房颤动的发生、维持和进展的细胞和分子电生理学。
Circ Res. 2014 Apr 25;114(9):1483-99. doi: 10.1161/CIRCRESAHA.114.302226.

引用本文的文献

1
Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management.用于心律失常管理的新型电活性治疗平台。
Adv Sci (Weinh). 2025 Jun;12(24):e2500061. doi: 10.1002/advs.202500061. Epub 2025 Feb 14.
2
Molecular remodeling in comorbidities associated with heart failure: a current update.与心力衰竭相关的合并症中的分子重构：最新进展。
Mol Biol Rep. 2024 Oct 26;51(1):1092. doi: 10.1007/s11033-024-10024-7.

本文引用的文献

1
TREK-1 (K2.1) K channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control.TREK-1（K2.1）钾通道在心房颤动和心力衰竭患者中受到抑制，并为节律控制提供治疗靶点。
Basic Res Cardiol. 2017 Jan;112(1):8. doi: 10.1007/s00395-016-0597-7. Epub 2016 Dec 22.
2
Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate.左心房后壁中显性负性转化生长因子-β II型受体的组成性表达导致心房颤动基质的有益重塑。
Circ Res. 2016 Jun 24;119(1):69-82. doi: 10.1161/CIRCRESAHA.115.307878. Epub 2016 May 23.
3
Biological Therapies for Atrial Fibrillation: Ready for Prime Time?心房颤动的生物疗法：准备好进入黄金时代了吗？
J Cardiovasc Pharmacol. 2016 Jan;67(1):19-25. doi: 10.1097/FJC.0000000000000293.
4
Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation.靶向非病毒基因抑制 Gα(i/o)-介导的后左心房迷走神经信号传递可减少迷走神经诱导的心房颤动。
Heart Rhythm. 2011 Nov;8(11):1722-9. doi: 10.1016/j.hrthm.2011.06.018. Epub 2011 Aug 25.
5
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.心房颤动的病理生理机制：转化评估。
Physiol Rev. 2011 Jan;91(1):265-325. doi: 10.1152/physrev.00031.2009.